India: Incremental Pharmaceutical Innovations: Impact On Public Health & Economy

Last Updated: 23 September 2013
Article by Priyanka Rastogi

Most Read Contributor in India, September 2016

Recently the Supreme Court of India rejected Novartis's appeal for Glivec patent protection stating that an "incremental innovation" is not protected under Section 3 (d) of Indian Patent Act, 1970 (hereinafter "the Act"). This judgment has compelled the pharmaceutical companies to rethink their move towards research and development (R&D) and to obtain patents in India. Our patent regime does not encourage or support the patenting of incremental innovations. Incremental Pharmaceutical Innovations (hereinafter "IPIs") have been stayed behind the economic growth and success of Indian pharmaceutical companies. Generally IPIs results in enhancement of the safety, efficiency of existing drugs and thus improving the quality of life of patients. Indefinite expression of section 3(d) of the Act limits the patentability of incremental innovation. Hence, amendment in section 3(d) of the Act is the need of the hour in order to bring some transparency in the patent regulation relating to pharmaceutical innovations. A patent system that generates spur to the incremental innovations can lead to cost decline and boost up the access to medicines by motivating the investment into domestic pharmaceutical research.


Under Section 3(d) of the Act, incremental pharmaceutical innovations—including new forms of known pharmaceutical substances—are not patentable unless they result in significantly enhanced "efficacy" of the active substance. The new invention must fulfill the patentability criteria i.e. novelty, inventive step and industrial applicability, in order to get a patent in India. Most of the incremental innovations satisfy the patentability criteria but still be unable to get patent because of the enhanced efficacy criteria set out by section 3(d). Thus majority of the IPIs are excluded by reducing the scope of patentability to only new forms of known substances and their derivatives which differ significantly in properties with respect to efficacy. The works "efficacy" and "significantly" used in section 3(d) are neither defined in the Act nor anywhere else in the guidelines to that effect. Therefore the manufactures/ inventors does not have any resource for knowing the required standard for patentability of the incremental innovation. More over pharmaceutical companies find it very hard to provide clinical data to demonstrate the therapeutic efficacy of the new form or new use of the drugs in the preliminary stages of drug development. It is obvious that present regime under section 3(d) is not favorable to incremental pharmaceutical innovation. Inconsistency in the wording of section 3(d) has to be resolved by including new use of a new form as patentable subject matter.

Section 3(d) is limiting the eligibility of incremental pharmaceutical innovations and resulting in discouragement in R&D for new routes of dose administration, new dosage forms, and other innovations that would result in the development of drug products that are well-suited to the needs of Indian patients.


Pharmaceutical innovations are of two types Radical and Incremental innovation. The former represents a separate new class of drugs which are having a novel mode of action, the latter also represents new drugs but in an already existing class, which have a similar mechanism as the first ones, however the incremental innovations differ in features such as, therapeutic profile, metabolism, adverse effects, dosing schedules, delivery systems, etc. While radical innovations are uniformly protected in all patent regimes, incremental innovation is generally regarded not worthy of protection because of the prevailing notion that they represent nothing more than the copies of existing molecules.

IPIs involve discovery of new forms and uses of known chemical compounds or substances, which results in to the safer, more effective and more useful drugs that are better suited to particular patient profiles and result in to improve patient compliance and greater overall wellbeing. Thousands of smaller incremental innovations set the basis upon which "blockbuster" drugs are originated. Discovery of penicillin is a good illustration of a radical pharmaceutical innovation that gave birth to potent new cure for bacterial diseases and instigated a new field of pharmaceutical research on antibiotics. US National Research Council has recognized that the cumulative effect of numerous minor incremental innovations can sometimes be more transformative and have more economic impact than a few radical innovations or technological break through1.


1. Clinical value of Incremental Pharmaceutical Innovation (IPI)

A study conducted in 2007 of the medicines on the WHO's Essential Drug List, found that over 60% of the drugs on the list reflect incremental Improvements of older drugs2. Incremental pharmaceutical innovation has the following clinical values:

  • Increased effectiveness, extended usefulness, and greater selectivity over prior known drug products;
  • Breakthrough drugs normally have side-effects and other restrictions, which are replaced by more effective incrementally improved versions;
  • Eradication or reduction of a treatment-limiting drug reaction;
  • Evidence of safety and effectiveness for a new patient subpopulation.
  • Increased effectiveness often is the result of incremental advances in dose delivery systems and dosage forms, such as transdermal delivery and extended release formulations, which can optimize the rate of absorption of a molecule and thereby maximize its therapeutic effect, while reducing toxicity and side-effects3.
  • More convenient dosing schedules which improve patient compliance.

2. Public Health & Socio-Economic implications: Improving quality life of Patients

The incremental pharmaceuticals innovations do have some prominent positive implications on the public health and our socio-economic conditions. Some of them are as below:

  • IPIs increases the numbers of different drugs in a specific class, thereby increases the price competition among those drugs and ultimately leading to drug price reduction. Thus this will make the drugs accessible to each and every section of the society.
  • Reduction in the overall cost of healthcare by improving the quality and selection of drugs available to the patients.
  • Boost the completion in the pharmaceutical industry leading to more research and development and new and better products to the consumers;
  • Increases revenue from incremental innovation which can be used to support the research & development of "blockbuster drugs"
  • New formulations and drug delivery systems specially developed which are specifically suited to Indian climate. For instance, use of microspheres for the controlled release of vaccines which make them resistant to extreme heat conditions could greatly help people living in remote areas of India where there is no refrigeration4.
  • Mashelkar Committee has also suggested that discouragement of incremental innovation could dissuade both Indian and foreign investors from investing in India5.


Incremental pharmaceutical innovation provides great support to the pharma companies to boost up research and development of the new drugs by offering opportunities to make profits by advancing the existing drugs. Consequently, elimination of incremental innovations from patent protection would cut the encouragement to modify the existing drugs and finally would affect the financial sources for new drug discovery. Incremental innovations also serve to enhance the safety and efficiency of existing drugs thereby improving the quality of life of patients. Indefinite wording of section 3(d) makes the patentability requirements for incremental innovation highly uncertain. Section 3(d) also acts as a disincentive for Indian pharmaceutical companies, who might otherwise capitalize on the economic opportunities presented by incremental pharmaceutical innovations in India and abroad.



2 J. Cohen et al., The role of follow-on drugs and indications on the WHO Essential 12 Drug List, 31 JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS 6,(2006)

3 See 20 Albert Wertheimer & Thomas Santella, "Pharmacoevolution: the advantages of incremental innovation," IPN Working Papers on Intellectual Property, Innovation and Health, International Policy Network (2005), at 8.


5 Report of the Technical Expert Group on Patent Law Issues, March, 2009, available at

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.